OxyContin OC 5mg – The Complete Medical Guide

OxyContin OC 5mg is an extended-release oxycodone formulation classified as a Schedule II controlled substance. As the lowest available strength of the original OxyContin formulation (pre-2010), it is designed for initiating therapy in opioid-tolerant patients requiring around-the-clock pain management. The “OC” designation indicates it lacks modern abuse-deterrent properties, requiring extra prescribing precautions.

Oxycontin OC 5mg

OxyContin OC 5mg is a prescription medication that contains oxycodone, an opioid analgesic, designed to provide long-lasting relief from moderate to severe pain. The “OC” formulation refers to the original controlled-release version of OxyContin, which is engineered to release the medication steadily over time, offering continuous pain relief.

Typically prescribed for chronic pain conditions, OxyContin OC 5 mg is ideal for patients who need around-the-clock pain management. However, due to its potency and risk of misuse, OxyContin should be used only as directed by a healthcare provider.

Key Benefits:

• Provides extended pain relief with controlled-release technology
• Effective for managing chronic pain
• Ideal for patients needing consistent, long-term pain control

Important Considerations:

• Risk of dependence, overdose, and misuse
• Common side effects include constipation, drowsiness, and dizziness
• Do not combine with alcohol or other sedatives

Consult with your doctor to determine if OxyContin OC 5 mg is the right choice for your pain management needs.

Medical Uses & Indications

FDA-Approved Uses

 Moderate to severe chronic pain requiring continuous opioid therapy
 Initiation of long-term opioid therapy in tolerant patients
 Pain uncontrolled by immediate-release opioids

Key Clinical Features

• Formulation: Original controlled-release (non-abuse deterrent)
• Onset: 1-2 hours
• Duration: 12-hour controlled release
• Equianalgesic ratio: 5mg q12h ≈ 7.5mg oral morphine daily
• DEA Classification: Schedule II (High abuse potential)

Pharmacology & Mechanism

Neurochemical Action

• Full μ-opioid receptor agonist
• κ-opioid receptor partial agonist
• Sustained activation of pain modulation pathways

Metabolic Profile

• Hepatic metabolism: CYP3A4 (major), CYP2D6 (minor)
• Active metabolites: Oxymorphone (via CYP2D6)
• Elimination half-life: 4.5-8 hours (ER formulation)

Dosing & Administration

Standard Protocol

• Initial dose for opioid-tolerant patients: 5mg q12h
• Titration: Adjust by 5mg increments every 3-7 days
• Maximum daily dose: 40mg without specialist consultation

Critical Safety Notes

 Not for opioid-naïve patients
 Never crush/chew tablets (immediate 5mg release risk)
 Naloxone co-prescription required
 Daily PDMP monitoring recommended

Safety Profile

Common Adverse Effects

• Constipation (prophylaxis required)
• Nausea/vomiting (30-40%)
• Dizziness/sedation
• Pruritus (20-25%)

Black Box Warnings

 High potential for addiction and abuse
 Life-threatening respiratory depression
 Accidental exposure danger
 Neonatal opioid withdrawal syndrome

Risk Mitigation Strategies

Prescribing Safeguards

1. Documented trial of non-opioid alternatives first

2. Written opioid treatment agreement

3. Weekly follow-ups for first month

4. Random urine drug screens

Patient Education

• Never share medication
• Recognize overdose signs
• Proper storage in locked container
• Avoid all CNS depressants

Clinical Alternatives

For Chronic Pain

• OxyContin OP (abuse-deterrent formulation)
• Xtampza ER (abuse-deterrent oxycodone)
• Morphine sulfate ER

Non-Opioid Options

• Duloxetine (For neuropathic pain)
• Gabapentin
• Interventional pain procedures

Special Population Considerations